Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.12
Bottom line from this bounded source set
The authors reported better functional recovery measures with Semax-containing care. Unclear allocation and masking, concurrent rehabilitation and incomplete harms reporting limit causal conclusions.12
Reviewed study record
Stroke rehabilitation and functional measures
Design
Patients in early and late rehabilitation groups were subdivided according to whether they received Semax.1
Population
The report included 110 people after ischemic stroke.1
Outcomes reported
The authors reported higher BDNF levels and better Barthel functional scores with Semax-containing care; rehabilitation timing also affected outcomes.1
Limitations
The abstract does not establish random allocation or masking and does not provide a detailed harms account. Concurrent rehabilitation and group differences may confound the findings.1
Reviewed study record
Acute ischemic stroke
Design
A clinical and electrophysiological comparison assessed Semax added to conventional intensive care.2
Population
Thirty Semax-treated patients were compared with eighty conventionally treated patients with reportedly similar stroke severity and lesion location.2
Outcomes reported
The authors described faster neurological recovery, particularly in motor measures.2
Limitations
The abstract does not clearly describe randomization, masking, a prespecified primary endpoint or adverse events. Unequal groups and combined care limit causal interpretation.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.17116/jnevro20181183261-68. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗